Compare Annaly Capital Management, Inc. (NLY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Annaly Capital Management, Inc. trades at $23.23 (market cap $17.27B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.8× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (13.09%). Which is the better fit depends on your goals.
| NLY | REGN | |
|---|---|---|
Market Cap | $17.27B | $83.19B |
Sector | Financials | Health |
52-Week High | $24.40 | $812.27 |
52-Week Low | $20.21 | $555.51 |
Dividend Yield | 13.09% | 0.47% |
Enterprise Value | — | $77.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Annaly Capital Management (NLY) trades at $23.04, up 1.68% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals with a P/E of 5.57, ROE of 20.66%, and a net income margin of 92.77%. Recent news highlights inclusion in Zacks' Strong Buy lists and a focus on high-yield income, supported by a $0.75 dividend payment scheduled for July 2026.
Outlook is positive with analyst consensus favoring Buy ratings (57.15%) and a $24.50 price target, implying ~6% upside. Key risks include interest rate sensitivity and mortgage market volatility, but diversified housing finance strategies and consistent dividend coverage provide stability. Investment appeal centers on value valuation and income generation.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
